TaiMed Biologics (4147.TWO) announced that its CEO, Dr. Jimmy Chang, has been invited to speak at Biologics CDMO Asia 2025, taking place in Singapore from September 10 to 11. Dr. Chang will present a talk titled “Advancing Antibody Therapeutics: Translating R&D into Scalable Commercial Manufacturing.”Recognized as one of Asia's most influential platforms for biologics and CDMO collaboration, the forum highlights advances in antibody and next-generation biologics development, manufacturing, and industry partnerships.

Dr. Chang's presentation will share TaiMed's end-to-end experience in bringing antibody therapeutics through development and commercialization. Key highlights include the development journey of Trogarzo®, the world's first FDA-approved HIV monoclonal antibody; critical challenges and key development, regulatory, and manufacturing considerations; and TaiMed's dual-track strategy of leveraging global CDMO collaborations alongside building in-house GMP manufacturing capacity to accelerate scale-up and ensure long-term supply security.

TaiMed's participation on this global stage underscores both its leadership in antibody drugs and its commitment to elevating Taiwan's biotechnology presence internationally. Dr. Chang remarked: "It is an honor to share TaiMed's experiences in antibody drug development and manufacturing at Biologics CDMO Asia. Through this exchange, we hope to showcase Taiwan's biotech innovation to the world while exploring new opportunities for collaboration to shape the future of biopharmaceutical development.